文献速递乳腺癌放疗

REQUITE队列乳腺癌放疗后早期与晚期CTCAE及患者报告结局

Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-10-07

REQUITE国际合作研究及其随访研究前瞻性收集接受放疗的乳腺癌、前列腺癌或肺癌患者的纵向数据。本文报告2057例乳腺癌女性患者的患者报告结局及急性和晚期不良反应,随访每年一次持续两年、符合条件中心延长至八年。结论认为REQUITE提供了常规分割与大分割放疗后急性和晚期结局的真实世界证据,与已发表随机试验大体一致。

要点

  • 急性不良反应在放疗结束时达峰,红斑发生率为83-89%。
  • 常规分割较大分割的≥2级急性疼痛(11%对4.3%)和皮肤溃疡(4.8%对0.8%)更常见。
  • ≥2级晚期不良反应影响0.6%-16.8%的患者,皮肤硬结最常见。

核心结论

  • REQUITE提供了乳腺癌患者接受常规分割和大分割放疗后急性和晚期结局的真实世界证据,与已发表随机试验大体一致。
  • 该数据集整合临床不良反应、生活质量、剂量学和遗传数据,可用于个体化放疗研究。

研究设计与样本

  • 国际REQUITE研究及其随访研究(RADprecise/REQUITEplus)前瞻性收集接受放疗的乳腺癌、前列腺癌或肺癌患者的纵向数据。
  • 入组要求包括无转移、既往五年内无其他恶性肿瘤、无既往乳腺照射;放疗前采血用于基因分型、分子分析和生物样本库。
  • 标准化评估包括CTCAE v4、EORTC QLQ-C30和BR23、MFI、GPAQ及DICOM/DVH数据;随访每年一次持续两年,符合条件中心延长至八年。

主要发现

  • 急性不良反应在放疗结束时达峰,红斑发生率为83-89%。
  • 常规分割较大分割的≥2级急性不良反应更频繁,包括疼痛(11%对4.3%)和皮肤溃疡(4.8%对0.8%)。
  • ≥2级晚期不良反应影响0.6%-16.8%的患者,皮肤硬结是最常见的晚期不良反应。
  • 患者报告结局评分随时间变化,两年时功能量表评分与基线相似或更高。

关键数值与推荐

  • 急性红斑发生率为83-89%。
  • ≥2级急性疼痛:常规分割11%对之大分割4.3%;≥2级急性皮肤溃疡:常规分割4.8%对之大分割0.8%。
  • ≥2级晚期不良反应影响0.6%-16.8%的患者,皮肤硬结最常见。

临床怎么用

  • 乳腺癌保乳术后放疗应关注放疗结束时的急性皮肤反应,红斑发生率高。
  • 选择常规分割时应告知患者≥2级急性疼痛和皮肤溃疡风险高于大分割。
  • 可利用该队列整合的临床、生活质量、剂量学与遗传数据支持个体化放疗研究。

局限性

  • 本文为观察性队列数据,非随机对照试验,分割方式比较可能受混杂因素影响。
  • 随访两年后仅在符合条件中心延长至八年,长期数据覆盖可能不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The international REQUITE study and its follow-up studies (RADprecise/REQUITEplus) prospectively collected longitudinal data from patients undergoing radiotherapy for breast, prostate, or lung cancer. We present data from 2057 women with breast cancer, describing patient-reported outcomes and acute and late adverse effects. METHODS: Patients were recruited between April 2014 and October 2016. Eligible patients received external-beam photon radiotherapy after breast-conserving surgery, had no metastasis at inclusion, no other malignancy within the previous five years, and no prior breast irradiation. Blood samples were collected before radiotherapy for genotyping, molecular analysis, and biobanking. Standardised assessments included CTCAE v4, EORTC QLQ-C30 and BR23, MFI, GPAQ, and DICOM/DVH data. Follow-up continued annually for two years, extending to eight years at eligible sites. RESULTS: Acute side effects peaked at end of radiotherapy, with erythema in 83-89% of patients. Grade ≥ 2 acute effects, including pain (11% versus 4.3%) and skin ulceration (4.8% versus 0.8%), were more frequent with normofractionation than hypofractionation. Grade ≥ 2 late effects affected between 0.6% and 16.8% of patients; skin induration was the most frequent late effect. Patient-reported outcome scores varied over time, with functional scale scores at two years similar to or higher than at baseline. CONCLUSION: REQUITE provides real-world evidence of acute and late outcomes following normo- and hypofractionation, broadly consistent with published randomised trials. The dataset, combining clinical adverse effects, quality of life, dosimetric, and genetic data, is a resource for personalised radiotherapy research (www.requite.eu).

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bockstiegel, Webb, Aguado-Barrera, et al. Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort. Clin Transl Radiat Oncol. 2026. PMID: 42935767. doi:10.1016/j.ctro.2026.101307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。